Emitents | Grindeks, AS (5299006DWR32NKWM1O86) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Veids | Finanšu pārskati | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Valoda | EN | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statuss | Publicēts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Versija | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Datums | 2015-11-27 18:02:16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Versijas komentārs | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Teksts |
Riga, Latvia November 27, 2015 Today, on 27 November, the JSC “Grindeks” submitted the non-audited consolidated financial statements for the nine months of 2015 to “NASDAQ Riga”. Non-audited financial results indicate that the Group’s turnover amounted to 63.5 million euros and has increased by 0.3 million euros or 0.6% in comparison to the first nine months of 2014. While the Group’s net profit, attributable to shareholders of the parent company, was 3.9 million euros in the first nine months of 2015 and has increased by 0.2 million euros or 5.7% in comparison to the three quarters of 2014. Gross profit margin in the three quarters of 2015 was 44% while net profit margin was 6.1%. In the nine months of 2015 the Group’s production was exported to 63 countries worldwide, a total of 56.9 million euros which is 2.8 million euros or 4.7% less than in the nine months of 2014. Statement of comprehensive income in the first nine months of 2015
Sales volume of the final dosage forms of “Grindeks” in the first nine months of 2015 was 56.5 million euros and has increased by 0.9 million euros or 1.6% in comparison to the first nine months of 2014. The sales amount in Russia, other CIS countries and Georgia reached 32.4 million euros in the first nine months of 2015, which is by 12.8 million euros or 28.4% less than in the first nine months of 2014. In comparison to the first nine months of the previous year the biggest increase in sales volumes has been reached in Armenia (20%), Georgia (39%), Kirgizstan (16%) and Turkmenistan (22%). Thanks to successful business diversification and the
development of company’s activities in new markets, turnover of the
final dosage forms in the Baltic States and other countries
amounted to 24.1 million euros, which is by 13.7 million euros or
2.3 times more than in the first nine months of 2014. The sales
volume in the Netherlands in comparison with first nine months of
2014 has increased 6.5 times, in Slovakia – 3 times, while in
Vietnam by 91%, Portugal – 89%, Poland – 56%. The sales volume in
Latvia in the first nine months of this year accounted to 4.7
million euros and has increased by 1.7 million euros or 57.1%
comparing with the first nine months of last year.
In the first nine months of 2015 “Grindeks” has
complemented its range of products and introduced the final dosage
form (capsule) of Ursodeoxycholic acid (UDCA) and started its
export to Russia and Georgia. Thereby “Grindeks” has widened its
offer in the gastrointestinal tract and metabolism drug therapeutic
group. “Grindeks” has also widened its range of food supplements
and introduced two new products – the latest generation lactic acid
bacteria and bifidobacteria complex Lactobex® Strong and
Herbastress® night. Both products are distributed in the
Baltics.
In the first nine months of 2015, sales of the
active pharmaceutical ingredients reached 5.8 million euros, which
is by 1.6 million euros or 22% less than in the first nine months
of 2014. Main markets of “Grindeks” active pharmaceutical
ingredients are the EU countries, USA, Canada and Japan. The most
required active pharmaceutical ingredients of “Grindeks” in the
first nine months of 2015 were Oxytocin, Zopiclone, Ftorafur
(Tegafur), Detomidine and Xylazine.
The Chairman of the Board Mr. Juris Bundulis: “Our
operations in the new markets are succeeding and bringing
remarkable results, approving that our business diversification
strategy is right. It is particularly pleasing that the sales
indicators in Latvia have increased by 57% comparing with the same
period last year. However, we have to admit that ongoing situation
and events in our key markets – Russian and Ukraine – is still
heavy affecting performance indicators of the joint stock company
“Grindeks”. Therefore, by expanding our operations in new markets,
using our experience and expertise the equal emphasis will be put
on the CIS countries as well.”
“Grindeks” photos:
http://www.grindeks.lv/en/for-media/gallery
About “Grindeks”
“Grindeks” is an international, vertically integrated
pharmaceutical company. Main fields of action are research,
development, manufacturing and sales of original products, generics
and active pharmaceutical ingredients. The Group of “Grindeks”
consists of five subsidiary companies in Latvia, Estonia, Russia
and Slovakia as well as representative offices in 13
countries.
“Grindeks” specializes in the heart and cardiovascular,
CNS and anti-cancer medication therapeutic groups. A range of
products covers a successful combination of original products and
generics, with the original products Mildronate® and Ftorafur® and
more than 100 forms of generics included therein. Currently
“Grindeks” produces 25 active pharmaceutical
ingredients.
Products of the company are exported to more than 60
countries and its export comprises 94% of the total turnover. The
main markets are: Russia and other CIS countries, the Baltic
States, the Netherlands, Germany, Canada, the U.S., France, Ireland
and Japan.
To increase production capacity and develop
infrastructure, since 2002 the company has accomplished many
significant investment projects, investing more than 70 million
euros over the years.
Further information:
Laila Klavina Head of the Communications Department, JSC “Grindeks” Phones: (+371) 67083370, (+371) 29256012 Fax: (+371) 67083505 laila.klavina@grindeks.lv |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pielikumi |